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Abstract This review summarizes the most relevant
articles from the field of neuro-ophthalmology published in
the Journal of Neurology from January 2012 to July 2013.
With the advent of video-oculography, several articles
describe new applications for eye movement recordings as
a diagnostic tool for a wide range of disorders. In myas-
thenia gravis, anti-Kv1.4 and anti-Lrp4 have been charac-
terized as promising novel autoantibodies for the diagnosis
of hitherto ‘seronegative’ myasthenia gravis. Several arti-
cles address new diagnostic and therapeutic approaches to
neuromyelitis optica, which further sharpen its profile as a
distinct entity. Additionally, 4-aminopyridine has become a
standard therapeutic for patients with cerebellar downbeat
nystagmus. Finally, revised diagnostic criteria have been
proposed for chronic relapsing inflammatory optic neuropathy
based on a careful literature review over the last decade.
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Ocular myasthenia gravis  Optic neuritis 
Neuromyelitis optica (NMO)  Chronic relapsing
inflammatory optic neuropathy (CRION)  Cerebellar
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Introduction
The eclectic field of neuro-ophthalmology keeps evolving
rapidly. In this article we are summarizing the most relevant
publications in the field published in the Journal of Neurol-
ogy from January 2012 to July 2013. The review is divided
into sections about the use of eye movement measurements
as a probe of disease, novel autoantibodies for the diagnosis
of myasthenia gravis, neuromyelitis optica (NMO) and
chronic relapsing inflammatory optic neuropathy (CRION)
and the therapeutic use of 4-aminopyridine.
Highlights
• Read-Right, a free web-based application (www.
readright.ucl.ac.uk) improves reading in patients
with right-sided hemianopia [4].
• The presence of nystagmus fast phases after
caloric irrigation predicts consciousness recovery
in patients with vegetative state on ICU [5].
• Anti-Kv1.4 [9] and anti-Lrp4 [11] are promising
novel autoantibodies for the diagnosis of hitherto
‘seronegative’ myasthenia gravis.
• While cyclosporine A may be effective in the
treatment of NMO [21], natalizumab may have
deleterious effects [22].
• 4-aminopyridine (4AP) and fampridine (sus-
tained-release form of 4AP) are effective treat-
ments of spontaneous and positional downbeat
nystagmus resulting from vestibulo-cerebellar
hypofunction [26, 27].
Eye movements as a probe of disease
The examination of eye movements is a rich source of
clinical information to neuro-ophthalmologists [1]. Thanks
to detailed knowledge of the underlying neurophysiologi-
cal circuits in the brainstem, eye movements provide
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precise information about the localization of disease and
often valuable clues about its etiology. With the advent of
video-oculography, quantitative analysis of eye movements
now becomes readily accessible to clinics.
Tseng et al. [2] devised a universally applicable patient
screening tool based on automated analysis of natural
viewing eye movements. The participants simply had to
watch television while their eye movements were recorded
with a head-mounted video-based eye tracker. The eye
movements were then analyzed for ocular motor features
such as saccade metrics, as well as visual attention based
on saliency maps. The investigators analyzed patient pop-
ulations from two different age groups: elderly people with
Parkinson’s disease as well as children with attention
deficit hyperactivity disorder (ADHD) and fetal alcohol
spectrum disorder (FASD). Based on eye movement
recordings from only 15 min of video, the method was able
to distinguish patients with Parkinson’s from age-matched
controls with an accuracy of 89.6 % and ADHD versus
FASD children with 77.3 % accuracy. While in Parkin-
son’s the distinction was made based on ocular motor
features, ADHD and FASD children were distinguished
based on visual attention features. The patient-friendly
nature of this automated test makes it a promising
screening tool for large populations.
In a population-based incidence cohort, Linder et al. [3]
looked at eye movements in patients with newly diagnosed
Parkinson syndrome before treatment. They examined 105
patients with Parkinson’s disease, 11 patients with progres-
sive supranuclear palsy (PSP) and 19 patients with multiple
system atrophy with predominant Parkinsonism (MSA-P).
The diagnosis was established by a movement disorder
specialist and supported by single-photon emission com-
puted tomography (FP-CIT SPECT). Analysis of square-
wave jerks, horizontal and vertical saccades and smooth
pursuit revealed pathological ocular motor function in all
patient groups. The ocular motor testing, however, could not
reliably differentiate different subtypes of Parkinson syn-
drome early in the course of the disease. Nevertheless, some
features, such as slow vertical saccade velocity or low
smooth pursuit gain, were found to be indicative of PSP.
Ong and colleagues [4] developed Read-Right, a free web-
based application (see www.readright.ucl.ac.uk) to improve
reading in patients with right-sided hemianopia. First, the
web application automatically assessed the visual field of the
patients. Then reading speed was measured with six stan-
dardized paragraphs of static text at baseline and after every
5 h of training. Reading training consisted of freely chosen
leftward scrolling text that could be adjusted in speed and
color. The rationale of the therapy was to induce involuntary
saccades into the patient’s blind right hemifield as a strategy
to improve reading when returning to normal, static text. With
this paradigm, the authors could demonstrate a significant,
training-dependent improvement of reading speeds of up to
46 % after 20 h of training. The free website provides a
promising approach to deliver reading training to the home of
patients when rehabilitation resources are scarce.
Predicting consciousness recovery in acute patients with
vegetative state (VS) is a diagnostic challenge on intensive
care units (ICU). Weiss et al. [5] investigated the prog-
nostic value of caloric bedside irrigation in 26 brain-injured
patients with VS. They found that the presence of quick
phases (rather than slow phases) of caloric nystagmus has a
very high positive predictive value of 0.93 for regaining
consciousness in these patients. The authors explain the
good correlation with the close anatomical relation
between the pathways of the vestibulo-ocular reflex and
consciousness in the brainstem. This indicator of a favor-
able outcome may be very helpful for guiding therapeutic
decisions on ICU. In another study, Trojano et al. [6]
explored the visual tracking behavior of chronic patients
with disorders of consciousness. Their goal was to distin-
guish patients with VS from patients with minimally con-
scious state, who have a more favorable outcome. The
authors found that patients with minimally conscious state
fixated significantly more on presented targets, while fix-
ation in patients with VS was at chance level. Quantitative
analysis of visual tracking behavior, as proposed by the
authors, may therefore be a promising tool for assessing
and following up patients with impaired consciousness.
Fatigue is one of the most common symptoms of mul-
tiple sclerosis (MS) with a substantial impact on the quality
of life of patients. Fatigue is usually assessed with the
fatigue severity scale (FSS), but objective measures of
fatigue are lacking. Finke et al. [7] set out to quantify
fatigue in MS patients with a saccadic fatigue task. They
asked MS patients with and without fatigue to continuously
perform saccades over a period of 10 min. They found that
patients with fatigue had a significantly larger decrease of
saccade peak velocity and amplitude than patients without
fatigue. For their study they used a portable infrared eye-
movement recording device, which would allow for con-
venient bedside testing of fatigue in a clinical setting. The
system, however, only provides ‘cyclopean’ recordings of
the average position of both eyes. As the authors
acknowledge, the presence of internuclear ophthalmoplegia
(INO), which is a frequent finding in MS, may interfere
with the result in these patients.
Novel myasthenia gravis autoantibodies
Ocular myasthenia gravis (MG) is often a diagnostic
dilemma, because autoantibodies to acetylcholine receptors
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(AChR) are negative in over 50 % of cases, repetitive
nerve stimulation of peripheral muscles has a poor sensi-
tivity, and single fiber electromyography as the current
gold standard is cumbersome and uncomfortable for the
patients. For these reasons, detection of additional auto-
antibodies would be very helpful in bridging the diagnostic
gap of hitherto ‘seronegative’ ocular MG.
A few years ago, novel autoantibodies to Kv1.4 have
been identified [8]. Kv1.4 is a subunit of the voltage-gated
potassium channel (VGKC) involved in the presynaptic
release of acetylcholine. The study has been done in a
Japanese population, where the antibodies were associated
with severe MG with bulbar involvement, myasthenic
crisis, thymoma, myocarditis, and QT prolongation on
electrocardiogram. Based on this study, Romi et al. [9] set
out to investigate the clinical features and serological
associations of anti-Kv1.4 antibodies in a Caucasian MG
population. They included samples from 129 myasthenia
gravis patients with mainly ocular symptoms. They could
detect anti-Kv1.4 antibodies in 17 % of their patients, most
of them women with late-onset MG. So, while in a Japa-
nese population, anti-Kv1.4 autoantibodies seem to be
associated with severe MG and thymoma, in Caucasians
the same antibodies are associated with mild, late-onset
MG in women. To reconcile this disparity, the authors
point out to the genetic differences between the two study
populations as a likely explanation.
Approximately 10 % of patients with generalized MG
have neither antibodies against AChR nor muscle-specific
tyrosine kinase (MuSK). However, onset and progression
of these so-called double-seronegative patients is very
similar to seropositive patients. As they respond similarly
to plasma exchange and immunosuppressive therapy, the
disease is likely caused by another pathogenic autoanti-
body. Recently, autoantibodies to low-density lipoprotein
receptor-related protein 4 (Lrp4) have been characterized
in patients with AChR-negative MG [10]. In this Japanese
population, anti-Lrp4 antibodies have been detected in only
nine out of 300 MG patients. Based on this study, Pevzner
et al. [11] analyzed sera from 13 double-seronegative MG
patients in a Caucasian population. In contrast to the pre-
vious study, they detected autoantibodies against Lrp4
much more frequently in about 50 % of their patients (7/
13) with a female preponderance and rather late onset.
Similar to the differences found for the anti-Kv1.4 anti-
bodies described above, the authors attributed the variation
to the different ethnical background of their patients.
In contrast to double-seronegative MG patients, double-
seropositive patients are exceedingly rare with only a
handful patients reported to date. Rajakulendran et al. [12]
described an interesting case with clinically biphasic MG
with both AChR and MuSK antibodies. The patient first
presented during adolescence with bulbar predilection
typical for AChR-positive MG. Following thymectomy she
went into complete remission. Fifteen years later, she
presented again, this time with severe oculo-bulbar, neck
and respiratory muscle involvement. She then had several
relapses that had to be treated with intravenous immuno-
globulins and plasma exchange. At this stage, the patient
was tested positive for both AchR and MuSK antibodies.
Although the authors could not prove that the patient was
MuSK-negative at initial presentation (as it was not tested),
they conjecture from the biphasic clinical course that she
switched from a predominantly AchR-mediated to a
MuSK-mediated phenotype after thymectomy. Based on
their experience, the authors recommend testing for MuSK
antibodies in MG patients who relapse after thymectomy as
this may substantially change their therapeutical approach.
Neuromyelitis optica (NMO) and chronic relapsing
inflammatory optic neuropathy (CRION)
Neuromyelitis optica (NMO) is a rare inflammatory and
demyelinating disease characterized by optic neuritis and
longitudinally extensive transverse myelitis. Euge`ne Devic
and his student Fernand Gault coined the term NMO in
1894 based on 16 patients with this rare association of
symptoms [13]. However, Jarius et al. [14] re-discovered
an earlier, forgotten report from 1804 by the French
pathologist and first physician to Louis XVIII, Antoine
Portal (1742–1832), who described a patient with visual
loss and spinal cord inflammation but no brain pathology.
In another paper, Jarius et al. [15] also highlighted the
seminal role of Sir Thomas Clifford Allbutt (1836–1925),
best known as the inventor of the clinical thermometer, in
piecing the NMO syndrome together based on three cases
with the same concurrence of symptoms published in 1870.
As NMO is a rare disease, reliable epidemiological data
has been quite sparse. Previous studies in different ethnic
groups reported variable prevalence rates between 3.2
(Japan) and 44/million (Denmark). Jacob et al. [16] estab-
lished the epidemiology of NMO in Merseyside, which is a
metropolitan county in North West England with the City of
Liverpool as its headquarters. The adult population of
Merseyside is about 1.1 million with 94.8 % Caucasians,
which is approximately representative for the UK in general.
Based on multiple overlapping data sources including hos-
pital records, central anti-aquaporin 4 (AQP4) antibody
testing laboratory data and the British Neurological Sur-
veillance Unit, they identified eight cases with NMO or
NMO spectrum disorder indicating a prevalence of 7.2/
million with an average annual incidence rate of 0.8/million.
Extrapolating to the whole UK population, the estimated
prevalence would correspond to 365 cases with an average
annual incidence rate of 39 cases. The authors point out that
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the relatively low prevalence compared to other studies
probably reflects genetic differences in the population
studied. Although the authors took great care in avoiding any
ascertainment bias by using overlapping data sources, they
admit that some NMO cases may have been missed mainly
because of misdiagnosis as multiple sclerosis (MS). Due to
increasing awareness of NMO and its varied spectrum, the
authors expect the prevalence to rise in the future.
To elucidate the time course of NMO, Uzawa et al. [17]
retrospectively analyzed a Japanese cohort of 43 patients
with a mean disease duration of 14.2 years. Myelitis and
optic neuritis were about equally frequent as initial
inflammatory events (44.2 and 41.9 %), while both toge-
ther occurred in about 9.3 %. Interestingly, myelitis was
found to be the more frequent initial symptom in older
patients ([50 years), whereas optic neuritis was seen more
often in younger patients (\50 years). By the end of the
observation period, 93 % of the patients had positive anti-
AQP4 antibody titers. The median interval from onset until
fulfillment of the 2006 NMO criteria [18] was 28 months,
indicating the difficulty for early diagnosis of the disease.
Based on this diagnostic delay of over 2 years, the authors
highlight the need for early diagnostic markers or more
specific criteria in order to initiate the appropriate treat-
ment timely.
According to the current diagnostic criteria [18], optic
neuritis and myelitis are absolute criteria for NMO. Exten-
sion of the myelitis over three or more vertebral segments
together with the presence of AQP4 antibodies and a brain
MRI that does not meet the criteria for MS further supports
the diagnosis of NMO. In a recent study Iorio et al. [19]
compared the clinical and neuroimaging characteristics of 37
patients with longitudinally extensive transverse myelitis. 16
of their patients had positive anti-AQP4 antibodies with a
higher female to male ratio than the negative patients. In
these patients the myelitis was often accompanied by
intractable nausea, vomiting and paroxysmal tonic spasms.
This was explained by the fact that the inflammatory lesions
extended into the brainstem more frequently involving the
central grey matter. These distinctive clinical features may
help to identify patients with NMO earlier in order to prompt
the appropriate treatment.
Despite many similarities with MS, the treatment of
NMO is different. Since randomized controlled trials for
the treatment of this rare disease are lacking, current
therapeutic concepts are still based on expert opinion and
consensus criteria [20]. While current best practice rec-
ommends oral treatment with azathioprine in combination
with corticosteroids, the efficacy of cyclosporine A has not
yet been evaluated in NMO. Kageyama et al. [21] reviewed
the clinical records of 52 patients with NMO spectrum
disorders and included 22 patients for analysis of their
treatment. First, the authors confirmed the efficacy of
azathioprine in combination with corticosteroids as a
treatment for NMO. Second, they provided the first evi-
dence that the combination of cyclosporine A and corti-
costeroids may be equally effective. Under treatment with
cyclosporine A, they observed a significant reduction in the
annual relapse rate as well as a decreased dose of con-
comitantly administered corticosteroids. In summary, the
case series provides the first retrospective evidence for the
efficacy of cyclosporine A in the treatment of NMO
spectrum disorders, but randomized controlled treatment
trials are warranted to confirm these results.
In a case report, Juryn´czyk et al. [22] reported the dele-
terious effect of natalizumab in a patient with initially
unrecognized NMO. The woman was diagnosed with MS at
the age of 22. She had recurrent relapses of spastic parapa-
resis, sensory deficits and severe right optic neuritis. Over the
years, she was treated with interferon b-1a, glatiramer ace-
tate and mitoxantrone. While she was in a stable condition,
she was then started on natalizumab. Six days after the fourth
infusion, she suddenly developed a severe relapse with
confusion, vomiting and paralysis of her left upper limb. Her
brain MRI showed an extensive, non-contrast-enhancing T2-
hyperintense lesion. Negative JC virus PCR ruled out pro-
gressive multifocal leukoencephalopathy. Based on the
presence of anti-AQP4 antibodies, the patient was finally
diagnosed with NMO according to the current criteria.
Treatment with plasmapheresis and intravenous methyl-
prednisolone led to clinical improvement with resolution of
confusion after 2 weeks. In line with previous reports, this
clinical case highlights that, following a few infusions, na-
talizumab may induce a severe relapse in patients with NMO.
The authors therefore recommend testing for anti-AQP4
antibodies in atypical MS patients, especially with severe
spinal and/or optic nerve involvement, before natalizumab
initiation and in patients who develop extensive brain lesions
during treatment.
Horwitz et al. [23] investigated the diagnostic value of a
lumbar puncture in patients with optic neuritis depending on
the result of visual evoked potential (VEP) and MRI exam-
ination of the brain. For this purpose, they retrospectively
analyzed 437 patients who presented with optic neuritis
without known MS prior to referral. They found that cere-
brospinal fluid (CSF) abnormalities (elevated leucocytes,
elevated IgG index or oligoclonal bands) correlated strongly
with pathological VEP and MRI results (P \ 0.0001). Vice
versa, they calculated that patients with both normal MRI
and VEP had a 96 % probability of normal CSF findings.
From their results they concluded that the diagnostic con-
tribution of a lumbar puncture to the evaluation of optic
neuritis is negligible in patients with normal VEP and MRI.
Therefore, the authors suggested that all patients with sus-
pected optic neuritis should be evaluated with VEP and MRI
before deciding on a lumbar puncture.
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Apart from NMO, the differential diagnosis of optic
neuritis includes the rare entity of chronic relapsing
inflammatory optic neuropathy (CRION), which was first
described by Kidd et al. [24] in 2003. In a systematic
literature review, Petzold et al. [25] now analyzed 122
patients with CRION over the last decade. They charac-
terized it as a rare, worldwide disease with a peak in the
fourth decade and a female preponderance. Typically,
patients presented with bilateral simultaneous or sequen-
tial, mostly severe visual loss and at least one relapse.
Pain at onset was reported in at least about a third of the
cases and particularly recurrence of pain after reducing or
stopping the steroids was noted as a red flag. Importantly,
most of the patients were negative for AQP4 antibodies,
suggesting that CRION is an entity distinct from NMO. In
addition, MRI scans of the brain did not show demye-
linating lesions typical for MS. Taken together, its etiol-
ogy still remains unknown, but seems likely to be
immune-mediated. All patients treated with methylpred-
nisolone responded, but relapsed after stopping the treat-
ment. Therefore, oral steroids had to be carefully tapered
under rigorous follow-up to identify the individual mini-
mal effective dose. As a consequence of the steroid-
dependency, steroid-sparing agents (azathioprine, metho-
trexate, cyclophosphamide or mycophenolate) had to be
used in many cases. But as a silver lining, in the expe-
rience of the authors, disease activity sometimes settled
over a decade. Based on their careful review with the key
points outlined above, they proposed revised diagnostic
criteria for CRION (Table 1). Since the diagnosis of
CRION based on these criteria remains mainly clinical
without any specific blood biomarker, the authors hope
for the discovery of a novel antibody, which would
facilitate early diagnosis and adequate treatment of the
disease.
Cerebellar downbeat nystagmus: treatment with 4-
aminopyridine
Hypofunction of the cerebellar flocculus causes––among
other ocular motor signs––downbeat nystagmus (DBN)
that, in turn, may lead to debilitating vertical oscillopsia. In
recent years, 4-aminopyridine (4AP), a potassium channel
blocker that increases Purkinje cell excitability, has
become a valuable therapeutic option to dampen cerebellar
DBN. 4AP also prevents attacks in episodic ataxia type 2
and improves cerebellar gait disorders. Fampridine is the
sustained-release form of 4AP. Only two doses per day are
required and cardiac side effects (prolonged QTc-time) are
less common than in 4AP. Fampridine is usually well tol-
erated by patients [26].
In patients with ataxia-telangiectasia (A-T), which typ-
ically involves the cerebellum, Shaikh et al. [27] studied
the effect of 4AP on ocular motor signs. 4AP reduced
deficits ascribed to the loss of cerebellar Purkinje cells in
these patients. Specifically, 4AP shortened the time con-
stant of the horizontal vestibulo-ocular reflex and
decreased spontaneous and periodic alternating nystagmus.
In a patient with a right posterior vermis lesion leading
to positional DBN and vertigo, 4AP was beneficial [28].
The lesion had caused hypofunction of the nodulus and
flocculus/paraflocculus, as demonstrated with FDG-PET.
This hypofunction was partly reversed by 4AP, which
suggests that the cerebellar structures inhibiting the upward
ocular drift bias were functionally restored by the
substance.
Another patient with a cerebellar ocular motor syndrome
showed a reversal of DBN into upbeat nystagmus (UBN)
after a test dose of fampridine [29]. Most likely, fampridine
caused a transient over-activity of Purkinje cell neurons in
this patient. This, in turn, increased the inhibition of
superior vestibular nuclei neurons, which predominantly
encode in the upward direction. Consequently, the eyes
drifted downward leading to UBN.
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